AQUESTIVE THERAPEUTICS INC. - COMMON STOCK

Aquestive Therapeutics Presented Positive Topline Phase 1 Results for AQST-109 Epinephrine Oral Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

28 Feb 2022 19:33:43 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

25 Feb 2022 06:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film

24 Feb 2022 20:26:14 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Fourth Quarter and Year End 2021 Financial Results and Recent Business Highlights on March 8 and Host Conference Call on March 9 at 8:00 a.m. ET

22 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

07 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company’s NDA for Libervant™ (diazepam) Buccal Film

20 Dec 2021 21:49:09 By Nasdaq GlobeNewswire

Aquestive Therapeutics Added to NASDAQ Biotechnology Index

17 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives Written Response to Pre-IND Submission for AQST-109 (epinephrine prodrug sublingual film) and Begins Recruitment for its Epinephrine Film Pharmacokinetic and Safety Trial (EPIPHAST)

13 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

17 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year Guidance

02 Nov 2021 15:30:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergic Reactions

25 Oct 2021 07:31:04 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Third Quarter 2021 Financial Results and Recent Business Highlights on November 2 and Host Conference Call on November 3 at 8:00 a.m. ET

14 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reaches Agreement to Extend Principal Payments Due Under Credit Facility to March 30, 2023 and Receives Bridge Waiver of Principal Debt Payment in Advance of Concluding Formal Agreement

06 Oct 2021 16:59:14 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Three Investor Conferences in September

07 Sep 2021 07:00:03 By Nasdaq GlobeNewswire

Aquestive Therapeutics Negotiates Six Month Extension to June 30, 2022 for Additional Libervant™ Related Capital Under Current Debt Agreement

09 Aug 2021 07:00:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in 12th Annual Wedbush PacGrow Healthcare Virtual Conference

06 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Second Quarter 2021 Financial Results, Provides Business Update and Raises Full Year Revenue Guidance

03 Aug 2021 16:54:56 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Second Quarter 2021 Financial Results and Recent Business Highlights on August 3 and Host Conference Call on August 4 at 8:00 a.m. ET

21 Jul 2021 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant™ (diazepam) Buccal Film

19 Jul 2021 08:29:40 By Nasdaq GlobeNewswire

Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film

24 Jun 2021 07:00:00 By Nasdaq GlobeNewswire